Tyrosine Phosphatase PTPRO Deficiency in ERBB2-Positive Breast Cancer Contributes to Poor Prognosis and Lapatinib Resistance

Despite the initial benefit from treating ERBB2-positive breast cancer with tyrosine kinase inhibitor lapatinib, resistance develops inevitably. Since the expression of protein tyrosine phosphatase receptor-type O (PTPRO), a member of the R3 subfamily of receptor protein tyrosine phosphatases (PTPs)...

Descripción completa

Detalles Bibliográficos
Autores principales: Dong, Hongmei, Du, Liang, Cai, Songwang, Lin, Wan, Chen, Chaoying, Still, Matthew, Yao, Zhimeng, Coppes, Robert P., Pan, Yunlong, Zhang, Dianzheng, Gao, Shegan, Zhang, Hao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9010868/
https://www.ncbi.nlm.nih.gov/pubmed/35431974
http://dx.doi.org/10.3389/fphar.2022.838171

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9010868/
https://www.ncbi.nlm.nih.gov/pubmed/35431974
http://dx.doi.org/10.3389/fphar.2022.838171

Ejemplares similares